4.1 Review

Insulin dysfunction and allostatic load in bipolar disorder

Journal

EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 11, Issue 7, Pages 1017-1028

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.185

Keywords

allostatic load; bipolar disorder; cognition; cytokines; early life stress; general medical comorbidities; HPA; insulin; neuroplasticity; oxidative stress

Funding

  1. Stanley Medical Research Institute
  2. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  3. Eli Lilly
  4. Janssen-Ortho
  5. Shire
  6. AstraZeneca
  7. Pfizer
  8. Bristol-Myers Squibb

Ask authors/readers for more resources

Bipolar disorder (BD) is associated with substantial morbidity, as well as premature mortality. Available evidence indicates that 'stress-sensitive' chronic medical disorders, such as cardiovascular disease, obesity and Type 2 diabetes mellitus, are critical mediators and/or moderators of BD. Changes in physiologic systems implicated in allostasis have been proposed to impact brain structures and neurocognition, as well as medical comorbidity in this population. For example, abnormalities in insulin physiology, for example, insulin resistance, hyperinsulinemia and central insulinopenia, are implicated as effectors of allostatic load in BD. Insulin's critical role in CNS physiological (e.g., neurotrophism and synaptic plasticity) and pathophysiological (e.g., neurocognitive deficits, pro-apoptosis and amyloid deposition) processes is amply documented. This article introduces the concept that insulin is a mediator of allostatic load in the BD and possibly a therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available